Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.

Suki Expands Ambient AI at the Point of Care with 20+ New Practices

What You Should Know: Suki, the leader in voice artificial intelligence (AI) technology for healthcare, today announces the expansion of its ambient clinical documentation solution to

October 31, 2023

Does an Additional First-Line Option Alter Approach in EGFR-Mutant NSCLC?

In August, the FDA approved another first-line treatment option for patients with EGFR-mutant non-small cell lung cancer (NSCLC): the third-generation EGFR tyrosine kinase inhibitor (TKI)

November 2, 2024

A novel approach to understanding protein compartmentalization

In physics, a system composed of two substances can be modeled in accordance with classical mixture theory, which considers the fraction corresponding to each constituent

October 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.